MM&M Therapeutic Focus: Cardiovascular
The list of top 50 CV products to emerge from "the Aughts" looks set for a shakeup entering "the Tens." Marc Iskowitz examines threats and opportunities expected from generic Lipitor and emerging CETP inhibitors, as well as market dynamics within the anti-platelet and anti-hypertensive segments
Your Email Address:
Recipient(s) Email Address:
(Separate multiple e-mail addresses with commas. Limited to 20 addresses.)
Include a message (optional):
The e-mail address(es) that you supply to use this service will only be used to send the requested article.